NextGen LiquiCORE 12 gene Panel

What is a NextGen LiquiCORE 12 Gene Panel? 

The NextGen LiquiCORE 12 Gene Panel is an advanced diagnostic blood test that uses Next Generation Sequencing (NGS) technology to analyse your blood for circulating tumour DNA (ctDNA) or cell-free DNA (cfDNA). This liquid biopsy test examines genetic material released by cancer cells into your bloodstream, providing valuable insights about your cancer's genetic makeup without requiring invasive tissue procedures. 

This test helps detect specific genetic mutations in 12 key genes commonly associated with solid tumours, particularly non-small cell lung cancer, enabling doctors to select the most effective targeted therapies for your treatment. 

What does the NextGen LiquiCORE 12 Gene Panel measure? 

This comprehensive liquid core lung panel measures several key aspects of cancer biology: 

• Actionable genetic mutations - Identifies specific changes in 12 genes that can guide targeted therapy selection. 

• Biomarkers for personalised treatment - Detects genetic signals that help doctors choose the most effective medicines for your specific cancer type. 

• Tumour evolution patterns - Monitors how cancer genetics change over time, helping track treatment response. 

• Drug resistance mechanisms - Identifies genetic changes that may affect how well certain treatments work. 

• Clinical trial eligibility markers - Determines if you may benefit from experimental treatments based on your cancer's genetic profile. 

NextGen LiquiCORE 12 Gene Panel: Who Needs It and Why It's Done 

What Symptoms May Call for a NextGen LiquiCORE 12 Gene Panel? 

This NGS sequencing test is not ordered based on initial symptoms but is recommended after cancer diagnosis. However, the original symptoms that may have led to cancer diagnosis include: 

• Persistent cough that worsens over time or doesn't improve 

• Coughing up blood or rust-coloured sputum 

• Chest pain that intensifies with deep breathing or coughing 

• Unexplained shortness of breath or wheezing 

• Persistent hoarseness or voice changes 

• Ongoing fatigue or weakness 

Who should get a NextGen LiquiCORE 12 Gene Panel? 

This specialised test is recommended for specific patient groups: 

• Patients with confirmed advanced cancer - Particularly those diagnosed with non small cell lung cancer to guide initial treatment planning. 

• Patients with treatment-resistant cancer - When current therapies aren't working effectively, helping identify new genetic changes. 

• Patients unsuitable for tissue biopsy - When traditional biopsy procedures are too risky or technically challenging. 

• Patients requiring treatment monitoring - To track how cancer genetics change during therapy and adjust treatment accordingly. 

• Patients considering clinical trials - To determine eligibility for experimental targeted therapies. 

Why is a NextGen LiquiCORE 12 Gene Panel done? 

This test enables precision medicine by creating a detailed genetic map of your cancer, allowing doctors to select targeted therapies that are more likely to be effective while causing fewer side effects than traditional chemotherapy. 

Importance of a NextGen LiquiCORE 12 Gene Panel 

The NextGen LiquiCORE 12 Gene Panel offers significant clinical benefits for cancer patients. As a minimally invasive liquid biopsy, it provides crucial genetic information through a simple blood draw, eliminating the health risks and discomfort associated with surgical tissue biopsies. 

This comprehensive test guides personalised treatment planning by identifying specific genetic mutations that respond to targeted therapies. For example, detecting EGFR mutations allows doctors to prescribe EGFR inhibitors, which are highly effective for cancers with this genetic alteration. The test also enables continuous monitoring of cancer evolution, helping doctors adjust treatment strategies as the disease changes over time. 

NextGen LiquiCORE 12 Gene Panel Booking & Reports – Metropolis Healthcare India 

How to Book a NextGen LiquiCORE 12 Gene Panel? 

1. Simple Online Booking 
   Booking can be done through the Metropolis Healthcare App or website. Select the NextGen LiquiCORE 12 Gene Panel, choose a convenient time slot, and provide your address for a blood test at home. You can also visit the nearest Metropolis Lab if you prefer to give the sample directly at the lab. 
    
2. Safe Home Sample Collection 
   Our trained phlebotomists ensure the timely collection of your sample while strictly following all safety and hygiene protocols. 
    
3. Sample Tracking Updates 
   Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website. 
    
4. Accurate Laboratory Testing 
   Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results. 
    
5. Quick & Easy Reports 
   Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app. 

Is home sample collection for NextGen LiquiCORE 12 Gene Panel available near you? 

Yes, Metropolis Healthcare brings the convenience of home blood sample collection directly to your doorstep across multiple cities. Our trained phlebotomists follow strict safety protocols while collecting your blood sample in the comfort of your home. This service eliminates the need to travel to a lab, making advanced genetic testing more accessible. 

How Long Does It Take to Get a NextGen LiquiCORE 12 Gene Panel Report? 

Reports are usually available after 20 days once the sample reaches the lab. 

Note: Reporting time may vary depending on your location. 

Where can I see or get NextGen LiquiCORE 12 Gene Panel results? 

Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp, and you also have the option to collect a physical copy directly from the lab. 

Interpreting NextGen LiquiCORE 12 Gene Panel Results 

What Your NextGen LiquiCORE 12 Gene Panel Results May Indicate 

Your test results will show whether specific genetic mutations were detected or not detected in each of the 12 genes analysed: 

Gene	Result Type	Detected	Not Detected
ALK	SNVs, short indels & Fusions	Mutation found - may guide targeted therapy selection	No mutation detected in this gene
BRAF	SNVs and short indels	Mutation found - may indicate specific treatment options	No mutation detected in this gene
EGFR	SNVs and short indels	Mutation found - EGFR inhibitors may be effective	No mutation detected in this gene
ERBB2	SNVs and short indels	Mutation found - may guide HER2-targeted therapy	No mutation detected in this gene
KRAS	SNVs and short indels	Mutation found - affects treatment response patterns	No mutation detected in this gene
MAP2K1	SNVs and short indels	Mutation found - may influence MEK inhibitor response	No mutation detected in this gene
MET-exon 14 skipping	SNVs, short indels, CNVs & Fusions	Mutation found - MET inhibitors may be considered	No mutation detected in this gene
NRAS	SNVs and short indels	Mutation found - affects treatment selection	No mutation detected in this gene
PIK3CA	SNVs and short indels	Mutation found - PI3K pathway targeted therapy considered	No mutation detected in this gene
TP53	SNVs and short indels	Mutation found - affects cancer behaviour and prognosis	No mutation detected in this gene
ROS1	SNVs, short indels & Fusions	Mutation found - ROS1 inhibitors may be effective	No mutation detected in this gene
RET	Fusions	Fusion found - RET inhibitors may be considered	No fusion detected in this gene

Conditions that May Affect NextGen LiquiCORE 12 Gene Panel Accuracy 

Several factors can influence the accuracy of your NextGen LiquiCORE 12 Gene Panel results: 

• Low tumour DNA levels - Not all cancers release detectable amounts of DNA into the bloodstream, potentially leading to false negative results. 

• Blood sample quality - Haemolysed, lipemic, or clotted samples can interfere with DNA extraction and analysis. 

• Recent treatments - Chemotherapy or radiation therapy may temporarily reduce circulating tumour DNA levels. 

• Sample timing - Very early-stage cancers may not shed enough DNA for detection. 

• Dehydration - Can concentrate blood components and affect sample quality. 

• Improper sample handling - Incorrect storage temperature or delayed processing can degrade DNA. 

• Tumour location - Some tumour locations may release less DNA into circulation than others. 

• Technical limitations - Rare polymorphisms or genetic variants may occasionally cause false results. 

How is a NextGen LiquiCORE 12 Gene Panel Done? 

The NextGen LiquiCORE 12 Gene Panel follows a simple blood draw procedure: 

• A healthcare professional cleans the area on your arm with an antiseptic. 

• An elastic band is tied around your upper arm to make the veins more visible. 

• A small needle is inserted into a vein to collect small amount of blood. 

• The blood sample is collected in a streck tube. 

• The needle is removed and a bandage is applied to the puncture site. 

• Your sample is labelled and sent to the pathology lab for analysis. 

• The entire procedure takes only a few minutes and causes minimal discomfort. 

How Should You Prepare for a NextGen LiquiCORE 12 Gene Panel? 

Preparing for your NextGen LiquiCORE 12 Gene Panel is straightforward: 

• No fasting required - You can eat and drink normally before the test. 

• Stay hydrated - Drink adequate water to ensure easy blood collection. 

• Inform about medications - Tell your doctor about all medicines, vitamins, and supplements you're taking. 

• Wear comfortable clothing - Choose clothes with sleeves that can be easily rolled up. 

• Bring clinical information - Ensure your detailed cancer history is available to the laboratory for accurate interpretation. 

• Continue regular medications - Unless specifically advised otherwise by your oncologist. 

Diseases that a NextGen LiquiCORE 12 Gene Panel Can Help Detect 

This advanced genetic panel assists in diagnosing and managing various health conditions: 

• Non-small cell lung cancer - Primary indication for this test, helping guide targeted therapy selection. 

• Solid tumours with actionable mutations - Various cancers that may respond to specific targeted treatments. 

• Treatment-resistant cancers - Identifies genetic changes causing resistance to current therapies. 

• Metastatic cancers - Provides genetic information when tissue biopsy from metastatic sites is difficult. 

• Hereditary cancer syndromes - Some detected mutations may indicate inherited cancer risks. 

• Tumour evolution patterns - Monitors how cancer genetics change during treatment progression. 

NextGen LiquiCORE 12 Gene Panel/Packages that You Can Book With Metropolis Healthcare 

Metropolis Healthcare offers comprehensive cancer genetic testing options to support your healthcare journey: 

Test/Package Name	Purpose/Highlights
Tumour Mutation Burden NGS	Assesses overall mutation load to guide immunotherapy decisions
Lung Cancer Targeted Therapy Panel (EGFR+ALK+ROS1)	Focused testing for three key lung cancer genes
NextGen Liquicore Paradigm Panel by NGS, Peripheral Blood	Provides comprehensive genomic profiling for cancer patients